Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

July 24, 2026

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-953-9590

Notice Concerning Partial Correction of “Notice Concerning Update to Mid-Term Management Plan” (Correction)

TAUNS Laboratories, Inc. hereby announces that it has identified certain matters requiring correction in the description on page 6 of the attachment to the “Notice Concerning Update to Mid-Term Management Plan” disclosed on July 15, 2026, titled “Factors for Operating Income Increase/Decrease from FY 2026/6 to FY 2031/6.” The corrections are as follows.

The full-year operating income forecast for the fiscal year ending June 30, 2026 remains unchanged at ¥4,368 million, as stated in the “Notice Concerning Revision of Full-Year Earnings Forecast” announced on March 30, 2026.

This correction is being made to standardize the presentation method for certain numerical figures in the “Notice Concerning Update to Mid-Term Management Plan,” as both rounded figures and truncated figures were used. The figures will be unified using truncated notation. There is no change to the full-year earnings forecast for the fiscal year ending June 30, 2026 or to the content of the Mid-Term Management Plan.

Item to be corrected	Before correction	After correction
Full-year operating income forecast for the fiscal year ending June 30, 2026	¥4.4 billion (¥4,368 million)	¥4.3 billion (¥4,368 million)

Please refer to the attached materials for details of the corrected items.

Details of Correction (Corrected items are underlined.)

(Before correction)

Factors for Operating Income Increase/Decrease from FY 2026/6 to FY 2031/6

- Beyond growth in respiratory -infection POCT, we aim to grow profit by launching new areas such as heart disease, cancer, and dementia.
- We will pursue productivity initiatives such as AIX to balance growth with cost efficiency.



(After correction)

Factors for Operating Income Increase/Decrease from FY 2026/6 to FY 2031/6

- Beyond growth in respiratory -infection POCT, we aim to grow profit by launching new areas such as heart disease, cancer, and dementia.
- We will pursue productivity initiatives such as AIX to balance growth with cost efficiency.